Arrowhead Pharmaceuticals (ARWR) Financial Analysis & Valuation | Quarter Chart
Arrowhead Pharmaceuticals (ARWR)
ARWRPrice: $78.11
Fair Value: 🔒
🔒score
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associat... more
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the ... more
Description
Shares
| Market Cap | $11.00B | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | US | CEO | Christopher R. Anzalone |
| IPO Date | 1993-12-16 | CAGR | 0.39% |
| Employees | 609 | Website | arrowheadpharma.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
ARWR chart loading...
Fundamentals
Technicals
| Enterprise Value | $10.11B | P/E Ratio | -32.69 |
| Forward P/E | -18.33 | PEG Ratio | — |
| P/S Ratio | 17.69 | P/B Ratio | 18.12 |
| P/CF Ratio | -306.4 | P/FCF Ratio | -216.27 |
| EPS | $-1.2 | EPS Growth 1Y | 50.7% |
| EPS Growth 3Y | 50.7% | EPS Growth 5Y | 101.89% |
| Revenue Growth 1Y | 14.09% | Gross Margin | 0.99% |
| Operating Margin | -0.36% | Profit Margin | -0.48% |
| ROE | -0.55% | ROA | -0.13% |
| ROCE | -0.11% | Current Ratio | 6.23 |
| Quick Ratio | 6.23 | Cash Ratio | 0.64 |
| Debt/Equity | 2.24 | Interest Coverage | -2.4 |
| Altman Z Score | 3.69 | Piotroski Score | 3 |